Diabetes Care Devices and Drugs Market Size, Share, and Growth Analysis, By Type (BGM Devices, Insulin Delivery Devices), By Distribution Channel (Hospital pharmacies, Retail Pharmacies), By End-use, By Region - Industry Forecast 2025-2032
당뇨병 케어 기기 및 약제 시장 규모는 2023년에 301억 8,000만 달러로 평가되며, 2024년 325억 6,000만 달러에서 2032년에는 598억 3,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 7.9%로 성장할 전망입니다.
국제당뇨병연맹에 따르면 약 5억 3,700만 명의 성인이 앓고 있는 전 세계에서 급증하고 있는 당뇨병 환자들에게 인슐린 조절을 통한 혈당 조절은 매우 중요한 문제입니다. 당뇨병, 특히 2형 당뇨병의 유병률 증가는 특히 중저소득 국가에서 비만율 증가, 건강에 해로운 식습관, 좌식 생활습관 등에 기인합니다. 이러한 환자 수 증가는 혈당 관리를 간소화하는 지속형 혈당 측정기를 포함한 당뇨병 관리 기기에 대한 수요를 크게 촉진하고 있습니다. 특히 2형 당뇨병 진단 건수가 증가함에 따라 의료비 지출이 증가함에 따라 시장은 성장할 것으로 예상됩니다. 시장 세분화는 이 중요한 헬스케어 부문에서 더 큰 시장 점유율을 확보하기 위해 인슐린 전달 장비를 강화하기 위한 기술 혁신에 대한 투자를 늘리고 있습니다.
목차
서론
조사 방법
- 정보 조달
- 2차와 1차 데이터 방법
- 시장 규모 예측
- 시장의 전제조건과 제한
개요
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 산업 분석
주요 시장 인사이트
- 주요 성공 요인
- 경쟁의 정도
- 주요 투자 기회
- 시장 에코시스템
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
당뇨병 케어 기기 및 약제 시장 규모 : 유형별 & CAGR(2025-2032)
- 시장 개요
- BGM 디바이스
- 자기 감시 디바이스
- 혈당 측정기
- 테스트 스트립
- 랜싯
- 연속 혈당 측정 기기
- 센서
- 송신기
- 수신기
- 인슐린 투여 기기
당뇨병 케어 기기 및 약제 시장 규모 : 유통 채널별 & CAGR(2025-2032)
- 시장 개요
- 병원 약국
- 소매 약국
- 당뇨병 클리닉/센터
- 온라인 약국
- 기타
당뇨병 케어 기기 및 약제 시장 규모 : 최종 용도별 & CAGR(2025-2032)
당뇨병 케어 기기 및 약제 시장 규모 : 지역별 & CAGR(2025-2032)
- 북미
- 유럽
- 독일
- 스페인
- 프랑스
- 영국
- 이탈리아
- 기타 유럽 지역
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 최근 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업의 기업 개요
- 기업의 상세
- 제품 포트폴리오 분석
- 기업의 부문별 점유율 분석
- 매출의 전년대비 비교(2022-2024)
주요 기업 개요
- Novo Nordisk(Denmark)
- Medtronic(Ireland)
- Abbott Laboratories(United States)
- Johnson & Johnson(United States)
- Biocon(India)
- Eli Lilly and Company(United States)
- Roche(Switzerland)
- Bayer(Germany)
- Dexcom(United States)
- Insulet Corporation(United States)
- Tandem Diabetes Care(United States)
- Ascensia Diabetes Care(Switzerland)
- Terumo Corporation(Japan)
- Becton, Dickinson and Company(United States)
- AstraZeneca(United Kingdom)
- Pfizer(United States)
- Merck & Co.(United States)
- GlaxoSmithKline(United Kingdom)
- McKesson Corporation(United States)
결론과 제안
KSA
Diabetes Care Devices and Drugs Market size was valued at USD 30.18 billion in 2023 and is poised to grow from USD 32.56 billion in 2024 to USD 59.83 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).
The management of blood glucose levels through insulin regulation is critical for individuals with diabetes, a rapidly rising global health concern affecting approximately 537 million adults according to the International Diabetes Federation. The increasing prevalence of diabetes, particularly type 2, largely stems from rising obesity rates, unhealthy diets, and sedentary lifestyles, especially in low- and middle-income countries. This growing patient population significantly drives the demand for diabetes care devices, including continuous glucose monitors, which simplify glucose management. The market is poised for growth as healthcare costs escalate alongside the rising number of diagnoses, particularly for type 2 diabetes. Manufacturers are increasingly investing in technological innovations to enhance insulin delivery devices, aiming to capture larger market shares in this vital healthcare segment.
Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetes Care Devices And Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Diabetes Care Devices And Drugs Market Segments Analysis
Global Diabetes Care Devices and Drugs Market is segmented by Type, Distribution Channel, End-use and region. Based on Type, the market is segmented into BGM Devices and Insulin Delivery Devices. Based on Distribution Channel, the market is segmented into Hospital pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies and Others. Based on End-use, the market is segmented into Hospitals, Diagnostic Centers and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Diabetes Care Devices And Drugs Market
One of the primary catalysts for the expansion of the global diabetes care devices and drugs market is the continuous introduction of innovative products aimed at diabetes monitoring and treatment. A notable example is the research conducted by the Universidade de Lisboa in Portugal, which demonstrated in April 2020 that coating insulin-loaded nanoparticles with chitosan could significantly improve the oral delivery of insulin. Furthermore, the rising investments in research and development, along with collaborative efforts in the field, are expected to provide additional opportunities for market growth, reinforcing the overall advancement of diabetes management solutions.
Restraints in the Diabetes Care Devices And Drugs Market
The growth of the global diabetes care devices and drugs market may be hindered by several factors, including limited reimbursement options, stringent regulations, and increasing obesity rates in certain regions. Additionally, the lack of awareness surrounding diabetes diagnosis and treatment, particularly in emerging markets, poses a significant challenge to market expansion. These obstacles can lead to reduced accessibility and adoption of diabetes care solutions, further impeding the development of the market. Addressing these issues will be essential to enhance growth prospects and improve the overall effectiveness of diabetes management strategies worldwide.
Market Trends of the Diabetes Care Devices And Drugs Market
The Diabetes Care Devices and Drugs market has experienced a notable positive trend, catalyzed by the COVID-19 pandemic, which heightened awareness and concern over diabetes management among patients. With diabetics facing elevated risks from the virus, the demand for advanced monitoring devices surged as individuals sought to manage their condition more effectively from home. This shift resulted in a significant increase in the adoption of home-based diabetes care solutions, driven by a desire to minimize hospital visits. As a result, the market has seen innovations in drug formulations and device technology aimed at improving blood glucose monitoring and overall diabetes management, indicating a sustained growth trajectory in response to evolving patient needs.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Diabetes Care Devices and Drugs Market Size by Type & CAGR (2025-2032)
- Market Overview
- BGM Devices
- Self-Monitoring Devices
- Blood Glucose Meters
- Testing Strips
- Lancets
- Continuous Glucose Monitoring Devices
- Sensors
- Transmitters
- Receiver
- Insulin Delivery Devices
- Pumps
- Pens
- Syringes and Needles
- Jet Injectors
Global Diabetes Care Devices and Drugs Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospital pharmacies
- Retail Pharmacies
- Diabetes Clinics/Centers
- Online Pharmacies
- Others
Global Diabetes Care Devices and Drugs Market Size by End-use & CAGR (2025-2032)
- Market Overview
- Hospitals
- Diagnostic Centers
- Homecare
Global Diabetes Care Devices and Drugs Market Size & CAGR (2025-2032)
- North America (Type, Distribution Channel, End-use)
- Europe (Type, Distribution Channel, End-use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Distribution Channel, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Distribution Channel, End-use)
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Distribution Channel, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocon (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dexcom (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Insulet Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tandem Diabetes Care (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ascensia Diabetes Care (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Becton, Dickinson and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- McKesson Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
